Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder" }, "data": [ { "type": "Grant", "id": "10487", "attributes": { "award_id": "3R00AT009466-04S1", "title": "Affective Sensory Pathways of Light Stroking and Deep Pressure Touch", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26496, "first_name": "Alexander H.", "last_name": "Tuttle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-06-01", "end_date": "2023-11-30", "award_amount": 219375, "principal_investigator": { "id": 26497, "first_name": "Laura K", "last_name": "Case", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Administrative Supplement Proposal: Abstract R00 AT009466: Affective Sensory Pathways of Light Stroking and Deep Pressure Touch Dr. Case is as an Assistant Professor in the Department of Anesthesiology at the University of California San Diego (UC San Diego). After overcoming covid-related delays, her R00 study on mechanisms of affective touch is running smoothly and on track with her current SARP. The proposed administrative supplement is requested to add two highly innovative aims to increase the impact of the originally proposed study in establishing novel mechanisms of action for sensory-based complementary approaches such as massage therapy. The existing R00 study seeks to identify factors underlying blunted affective touch perception in individuals with chronic pain, and to compare the pain-relieving mechanisms and effects of light gentle stroking and deep pressure between patients with Fibromyalgia (FM) and healthy controls. The current administrative proposal adds two aims: 5) Determine the local effect of subcutaneous OT on experimental pain and 6) Determine the local effect of subcutaneous OT on touch pleasantness. Recent research in rodents demonstrates that oxytocin strongly modulates C-fibers in the spinal cord and at the terminal axon. In humans, systemic oxytocin modulates affective touch perception, and skin injection reduces postsurgical pain. However, peripheral effects of oxytocin on affective touch perception have never been tested in humans. Study results are expected to significantly impact fundamental understanding of the mechanisms of peripheral pathways for touch pleasantness and pain reduction. We expect this project to lead to a competitive R01 submission to test whether local effects of oxytocin differ in patients with chronic pain, who exhibit C-nociceptor sensitization and reduced touch pleasantness. This contribution will inform subsequent research on mechanisms of manual touch therapies and provide a new direction to test differences in individuals with chronic pain.", "keywords": [ "Acute Pain", "Administrative Supplement", "Adult", "Affective", "Analgesics", "Anesthesiology", "Anxiety", "Area", "Attention", "Blood", "C Fiber", "California", "Clinical Treatment", "Cross-Over Studies", "Dorsal", "Dose", "Double-Blind Method", "Emotional", "Enrollment", "Enzyme-Linked Immunosorbent Assay", "Esthesia", "Exhibits", "Forearm", "Fright", "Heart Rate", "Human", "Immunoassay", "Individual", "Injections", "Institutional Review Boards", "Insula of Reil", "Isotonic Exercise", "Lead", "Light", "Manipulative Therapies", "Manuals", "Massage", "Measures", "Mechanics", "Mechanoreceptors", "Mediating", "Mediator of activation protein", "Moods", "Mus", "Nerve", "Neurons", "Neuropeptides", "Nociception", "Nociceptors", "Opioid Antagonist", "Oxytocin", "Oxytocin Receptor", "Pain", "Pain Threshold", "Pain intensity", "Participant", "Pathway interactions", "Perception", "Peripheral", "Placebos", "Postoperative Pain", "Predictive Factor", "Presynaptic Terminals", "Process", "Research", "Rodent", "Role", "Running", "Saline", "Sensory", "Skin", "Spinal Cord", "Spinal Ganglia", "Stimulus", "Stress", "Tactile", "Testing", "Therapeutic tactile stimulation", "Touch sensation", "Transcranial magnetic stimulation", "Universities", "autism spectrum disorder", "base", "chronic pain", "chronic pain management", "chronic pain patient", "coronavirus disease", "experience", "fibromyalgia patients", "injured", "innovation", "light effects", "nerve injury", "novel", "pain behavior", "pain model", "pain perception", "pain reduction", "pain relief", "painful neuropathy", "peripheral pain", "pressure", "professor", "programs", "social", "subcutaneous", "tactile stimulation", "theories", "trait" ], "approved": true } }, { "type": "Grant", "id": "10519", "attributes": { "award_id": "1R43IP001195-01", "title": "mRNA-BASED VACCINE AGAINST MULTIPLE COVID-19 VARIANTS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-09-29", "award_amount": 252010, "principal_investigator": { "id": 26528, "first_name": "Mohammed", "last_name": "Bouziane", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1937, "ror": "", "name": "SUNOMIX THERAPEUTICS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Over the last 25 months humanity has been confronting COVID-19 pandemic caused by the new Corona Virus 2 (SARS-CoV-2) infection. Mutations and deletions often occur in the genome of SARS-CoV-2 (predominantly in the Spike protein) resulting in more transmissible and pathogenic “variants of concern” (VOCs). Our long- term goal is to develop a potent COVID-19 vaccine to stop/reduce SARS-CoV-2 infections and/or COVID-19 disease caused by multiple VOCs. Major gaps: Out of the 50 mutations that occur in the genome of OMICRON variant, 32 mutations are concentrated in the Spike protein sequence alone. Because most mutation and deletion that produced the 20 known VOCs are mostly concentrated on the Spike protein sequence, there is a risk that some of current COVID-19 sub-unit vaccines, that used mainly the Spike protein as antigen, fail to protect against future VOCs despite inducing strong virus-specific neutralizing antibodies. This emphasizes two major gaps in knowledge: The need to design alternative second-generation coronaviruses vaccines that (1) will include non- structural epitopes and antigens (Ags), other than the Spike protein; and (2) will incorporate conserved B and T cell epitopes to induce cell-mediated immune responses (in addition to humoral responses). Preliminary Results: We: (1) Identified potential human T cell target epitopes (the part of a virus antigens that the immune system recognizes) from the whole SARS-CoV-2 genome; and (2) Produced a first prototype multi-epitope COVID-mRNA vaccine candidate using the scalable and proven mRNAs vaccine platform, and (3) Generated a novel “humanized” susceptible HLA-DR/HLA-A*0201/hACE2 triple transgenic mouse model in which to test additional COVID-mRNA-based vaccine candidates. We hypothesize that one of our 5 COVID-19 vaccine candidates will protect “humanized” mice from infection and COVID-like disease caused by intranasal inoculation with SARS-CoV-2 a, b, g, d and Omicron VOCs. Our Specific Aims are: Aim 1: To construct 5 additional multi- epitopes COVID-mRNA-based vaccine candidates, that will incorporate conserved B and T cell epitopes from SARS-CoV-2 VOCs that circulate in the United Sates and other 200 other countries. Aim 2: To test in our novel “humanized” mouse model the safety, immunogenicity, and protective efficacy against SARS-CoV-2 a, b, g, d or Omicron VOCs of 5 multi-epitope COVID-mRNA vaccine candidates, delivered intranasally. The durability of protection and its correlation with blocking/neutralizing antibodies and the number and function of tissue-resident SARS-CoV-2-specific CD4+ and CD8+ TRM cells in the lungs and brains will be determined. If successful, the lead vaccine that protects against most VOCs, will be tested in non-human primate for safety (SBIR Phase II) and subsequently could be moved quickly into an FDA Phase 1 clinical trial.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10503", "attributes": { "award_id": "3U24HG007008-09S1", "title": "Institute of Human Virology H3Africa Biorepository (I-HAB) ADMIN SUPPLEMENT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26498, "first_name": "Jennifer L", "last_name": "Troyer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2023-06-30", "award_amount": 345798, "principal_investigator": { "id": 22793, "first_name": "Alash'le G.", "last_name": "Abimiku", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1539, "ror": "https://ror.org/02e66xy22", "name": "Institute of Human Virology", "address": "", "city": "", "state": "", "zip": "", "country": "NIGERIA", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1539, "ror": "https://ror.org/02e66xy22", "name": "Institute of Human Virology", "address": "", "city": "", "state": "", "zip": "", "country": "NIGERIA", "approved": true }, "abstract": "The Institute of Human Virology Nigeria (IHVN) H3Africa biorepository (I-HAB), has successfully upgraded its practices to be ISBER compliant through an iterative quality assessment-based interaction involving capacity building drawing upon Coriell’s proven models and graduated to be the W/Africa H3Africa regional biorepository, During the COVID-19 pandemic, I-HAB lost 18 months of its planned activities due to the disruption of services by the pandemic. So far, I-HAB has only successfully received and aliquoted all DNA biospecimens from only one of the six H3Africa research projects that it supports. Two of the projects deposited 67% and 86% while the rest of the three projects are below 50% submission; at only 0%, 17%, and 29%. The goal of this administrative supplemental submission (1 JULY 2022 TO 30 JUNE 2023) is to ensure that all remaining biospecimens are deposited by H3Africa investigators, aliquoted, and used in the final phase which is to distribute aliquoted biospecimens and data to investigators from the wider scientific community whose application has been approved by the Data and Biospecimen Advisory Committee (DBAC) to conduct high-quality genomics and translational research in Africa using well processed, preserved and quality controlled and redundantly protected human biological samples. To achieve this, I-HAB builds on its past successes to address four specific aims. 1) Engage PIs to complete deposition and create sub-aliquots of primary human biologic samples and genetic materials in compliance with GLP, ISBER guidelines, and QC 10% in line with H3Africa policies/ guidelines. 2) Populate, interrogate, and query the database regularly to ensure that the online catalogue is up to date, interfacing regularly with other two regional H3Africa biorepositories, the H3AfricaBionet team, and relevant stakeholders to review and brainstorm on ways to address gaps during scheduled meetings. 3) Pilot processes for efficient distribution of high- quality biological samples to the wider scientific community, based on Data and Biological samples Access Committee approval and according to H3Africa policies and guidelines. 4) Strengthen I-HAB’s business model as part of a long-term sustainability strategy. Working collaboratively with the other two sister H3Africa biorepositories and the H3Africa Bionet, I-HAB continues to advocate for host government and community support and pilot processes to make the regulatory and ethical process of sharing samples and data easier. The strong institutional support through the expansion of the biorepository to over 3times its size at IHVN’s new facility, the acquirement of a liquid nitrogen plant, and the expansion of its clientele to investigators outside of H3Africa signals a sustainable future for I- HAB.", "keywords": [ "Address", "Administrative Supplement", "Advisory Committees", "Advocate", "Africa", "African", "Aliquot", "Bioinformatics", "Biological", "Businesses", "COVID-19 pandemic", "Catalogs", "Clinical Data", "Communities", "DNA", "Data", "Deposition", "Disease", "Ensure", "Ethics", "Future", "Genes", "Genetic Materials", "Genomics", "Goals", "Government", "Grant", "Guidelines", "Health", "Human", "Human Resources", "Infrastructure", "Institutes", "Leadership", "Liquid substance", "Mentors", "Modeling", "Nigeria", "Nitrogen", "Persons", "Phase", "Plants", "Policies", "Population", "Process", "Public Health", "Race", "Research", "Research Personnel", "Research Project Grants", "Resources", "Rest", "Sampling", "Schedule", "Science", "Scientist", "Services", "Shipping", "Signal Transduction", "Sister", "Time", "Training", "Translational Research", "Work", "base", "biobank", "clinical research site", "database query", "epidemiologic data", "global health", "high standard", "improved", "meetings", "pandemic disease", "preservation", "sample collection", "success", "virology" ], "approved": true } }, { "type": "Grant", "id": "10583", "attributes": { "award_id": "1U01CK000675-01", "title": "TRANSMIT: Training Research Acumen iN Students Modeling Infectious Threats", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2025-09-29", "award_amount": 297120, "principal_investigator": { "id": 26605, "first_name": "Frederick R.", "last_name": "Adler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26606, "first_name": "Lindsay T.", "last_name": "Keegan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26607, "first_name": "DAMON", "last_name": "TOTH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26608, "first_name": "YUE", "last_name": "ZHANG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "The ongoing COVID-19 pandemic has overwhelmed healthcare and public health systems, underscoring the need to anticipate disease outbreaks and prepare resources such as hospital beds and staff. One cost-effective and timely way to prepare resources to respond to these outbreaks is through the use of mathematical modeling. Models can act as a virtual laboratory to explore a variety of scenarios, interventions, or applications in a timely manner to inform policy interventions. While the COVID-19 pandemic highlighted the gaps that models can fill, it also highlighted a considerable gap in modeling: there is a lack of modeling professionals trained in developing and applying transmission models to healthcare settings. In this proposal, we detail three projects aimed to train three predoctoral fellows in different aspects of mathematical modeling of healthcare associated pathogens. These projects tackle different pathogens and components of disease transmission in a healthcare setting; and, while each project is distinct, they dovetail nicely, resulting in a cohesive research program. Project 1 tackles a critical component of disease transmission in healthcare settings: COVID-19 in long-term care facilities (LTCFs). Throughout the pandemic, LTCFs bore a disproportionate burden of mortality. Yet, while it is clear that LTCFs important with regards to disease outcomes, whether or not they exert selective forces on SARS-CoV-2 that have shaped global patterns of pathogen evolution is not yet known. Here, we will develop models to quantify the phylogenetic relationships between community and long-term care facility lineages to understand the viral diversification attributable to healthcare settings. Project 2 explores the risk factors of patients hospitalized with SARS-CoV-2 for acquiring multi-drug resistant organisms (MDROs). The rapid spread of SARS-CoV-2 has changed to hospital infection control and antimicrobial stewardship policies. One such change has been widespread potentially unnecessary antibiotic use among hospitalized patients. Here, we will identify the characteristics of the sub-population disproportionately impacted by co-infections with MDROs for patients hospitalized with SARS- CoV-2. Project 3 integrates with both Project 1 and 2, to explore the evolution of antibiotic resistance due to variable dose and off-target antibiotic use in healthcare settings. Patients in hospitals and residents of LTCFs are exposed to a wide range of pathogens and treatments, and many of these organisms have themselves been exposed to a wide range of environmental antibiotics. Here, we will develop models of evolution to investigate the conditions that lead to the most intractable infections.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10471", "attributes": { "award_id": "3F31CA224806-04S1", "title": "Redox modulation - Impact on Tumor Growth and Therapeutic Anticancer Efficacy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24807, "first_name": "ANTHONY THOMAS", "last_name": "Dibello", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-03-01", "end_date": "2023-02-28", "award_amount": 26352, "principal_investigator": { "id": 26482, "first_name": "Michael Yi", "last_name": "Bonner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1936, "ror": "https://ror.org/056d84691", "name": "Karolinska Institute", "address": "", "city": "", "state": "", "zip": "", "country": "SWEDEN", "approved": true }, "abstract": "Despite advances in cancer biology, drug resistance is a major obstacle to patients and clinicians. Many cancer therapeutics elevate reactive oxygen species (ROS) production, often leading to regression followed by reoccurrence and therapeutic resistance. This project continues work published by Kelkka et al. which observed tumor growth inhibition in mice carrying a loss of function mutation in the Ncf1 molecule of the Nox2 complex (Kelkka, T. et al. 2013). Given that Ncf1 mutant mice are more susceptible to animal models of human autoimmune diseases (Zhong, J. et al. 2018), immune cells may be more efficacious against metastasis and tumor progression when ROS production in leukocytes is inhibited. However, their studies did not identify which leukocyte plays the major role in the Nox2-mediated tumor growth, presenting possible targets for cancer therapy. Currently five clinical trials are evaluating Auranofin, an FDA approved thioredoxin reductase 1 (TrxR) inhibitor, as a possible treatment for malignancies such as glioblastoma, ovarian cancer, lung carcinoma, and leukemia. Earlier studies have shown that inhibition of TrxR in tumors suppresses, in vivo tumor progression (Stafford, W. C. et al. 2018, Yoo, M. H. et al. 2006). However, these studies, and a vast majority of studies to-date, have limited testing of Auranofin to immuno-compromised animal models. We have strong evidence that TrxR inhibition in immune-competent animals significantly promote tumor growth of solid murine syngeneic tumors such as the B16F10 melanoma and the Lewis Lung Carcinoma (LLC) models. Our studies are supported by overlooked, yet convincing studies in the literature (Hiramoto, K. et al. 2014, Mirabelli, C. K. et al. 1985). Therefore, we also aim to show that inhibition of TrxR in dendritic cells or B cells may promote tumor progression. This reorganized PhD project, having been heavily affected by COVID due to dependence on multiple breeding, will finalize experiments for two high-impact manuscripts for publication aimed at journals such as Cell or Immunity: 1) A manuscript establishing the therapeutic potential of targeting Ncf1-Nox2 in syngeneic dendritic cells for use against B16F10 and LLC cancer models; 2) a manuscript establishing the effects of TrxR1 inhibition in dendritic cells and mechanism for promoting B16F10 and LLC tumor growth, and its implication for anticancer therapy. We will use six mouse strains to help us understand the significance of host Redox biology in cancer immune surveillance. Specifically, we will use mouse models with key phenotypes: BQ.Txnrd1Flox, BQ.Ncf1m1J (Ncf1 mutant mice), BQ.CD11c-cre, BQ.MB1-cre, BQ.CD4-cre, and BQ.TN3 conditional Ncf1 wildtype knock- in mice. If successful, this will be of therapeutic significance.", "keywords": [ "Adoptive Transfer", "Affect", "Animal Model", "Animals", "Antigens", "Antioxidants", "Auranofin", "Autoimmune Diseases", "B-Lymphocytes", "Biology", "Breeding", "Cancer Biology", "Cancer Model", "Cancer Patient", "Cells", "Clinical", "Clinical Trials", "Complex", "Cysteine", "Dendritic Cells", "Dependence", "Development", "Doctor of Philosophy", "Drug resistance", "FDA approved", "Genetic", "Glioblastoma", "Growth", "ITGAX gene", "Immune", "Immunity", "Immunocompetent", "Immunocompromised Host", "Immunologic Surveillance", "Journals", "Knock-in Mouse", "Knock-out", "Knowledge", "Leukocytes", "Lewis Lung Carcinoma", "Lewis lung carcinoma cell", "Literature", "Malignant - descriptor", "Malignant Neoplasms", "Malignant neoplasm of ovary", "Manuscripts", "Mediating", "Modeling", "Mouse Strains", "Mus", "Mutant Strains Mice", "Mutation", "Neoplasm Metastasis", "Nuclear", "Organism", "Oxidation-Reduction", "Patients", "Pharmacology", "Phenotype", "Play", "Production", "Proteome", "Proteomics", "Publications", "Publishing", "Reactive Oxygen Species", "Research Project Grants", "Role", "Solid", "System", "Testing", "Therapeutic", "Work", "anti-cancer therapeutic", "cancer therapy", "cell transformation", "coronavirus disease", "experimental study", "human model", "improved", "in vivo", "inhibitor", "insight", "leukemia", "loss of function mutation", "lung Carcinoma", "melanoma", "mouse model", "mutant", "premalignant", "public health relevance", "targeted cancer therapy", "therapy resistant", "thioredoxin reductase 1", "transcription factor", "tumor", "tumor growth", "tumor progression" ], "approved": true } }, { "type": "Grant", "id": "10415", "attributes": { "award_id": "1S06GM146122-01", "title": "Environmental Influences Driving Autoimmunity and Autoimmune Disease in Tribal Members", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-20", "end_date": "2026-07-31", "award_amount": 372113, "principal_investigator": { "id": 10936, "first_name": "JUDITH A", "last_name": "JAMES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1109, "ror": "", "name": "UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1813, "ror": "https://ror.org/00p23dy23", "name": "Cherokee Nation", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true }, "abstract": "OMRF Project Summary Rheumatic diseases, such as systemic lupus erythematosus (SLE, lupus), rheumatoid arthritis (RA), scleroderma and osteoarthritis, cause significant morbidity and early mortality in Native American populations. Through ongoing collaborative work between the Cherokee Nation and the Oklahoma Medical Research Foundation, we have found that classic autoantibody associations in rheumatic disease patients of other races are not diagnostic in NA populations, identified novel autoantibodies in tribal rheumatic disease patents and found that tribal patients and controls have unique cytokine signatures; all of which make rheumatic disease care in tribal members more challenging to diagnose in primary care clinics. Surprisingly, we found that Native American individuals without evidence of autoimmune rheumatic disease had the highest rate of autoantibody production (10.5%) of all races, primarily with lupus, systemic sclerosis or rheumatoid arthritis associated antibodies. Autoantibody production is associated with lower levels of 25(OH)D in these individuals. Anti- cardiolipin autoantibodies are also more frequent in NA rheumatic disease patients and controls. Some of the highest rates of infection, poor outcomes and deaths from COVID have occurred in tribal communities, and COVID induces autoantibodies in many otherwise healthy individuals, including anti- cardiolipin responses that associate with thrombosis and anti-cytokine responses that associate with poor disease outcomes. In studies from our group and others, many COVID patients with autoimmunity or autoimmune disease are having prolonged symptoms, which are reminiscent of rheumatic diseases, such as fatigue, arthralgias, myalgias, malaise, rashes, lung and heart involvement. Select environmental factors have strong associations with systemic autoimmune rheumatic diseases. This project will define the impact of environmental influences, such as viral infections (SARS-CoV-2, Epstein-Barr virus, Cytomegalovirus), viral reactivation (Epstein-Barr virus), vitamin D deficiency and smoking exposure, on the development of autoantibodies and autoimmune disease in tribal members. Using single cell mass cytometry time of flight (CyTOF) and single cell genomic sequencing partnered with antibody binding (CITE-seq), shared immune pathways contributing to loss of self-tolerance, autoantibody production and autoimmune rheumatic disease will be determined. Finally, through implementation of a telerheumatology, telementoring program focused on practice-centric, case-based learning, academic detailing, and patient enrollment to clinical research protocols rheumatology capacity within the Cherokee Nation Health System will be developed for current and future patients. The overall goals of this project are to identify and confirm environmental influences associated with autoantibody production, immune dysregulation and autoimmune rheumatic disease, as well as build lasting tribal-based infrastructure to provide ongoing rheumatic disease evaluation and treatment that aid earlier detection, decreased morbidity and improved outcomes in tribal patients.", "keywords": [ "2019-nCoV", "Academic Detailing", "Algorithms", "Antibodies", "Arthralgia", "Autoantibodies", "Autoimmune", "Autoimmune Diseases", "Autoimmunity", "Automobile Driving", "Binding", "COVID-19", "COVID-19 impact", "COVID-19 patient", "Caring", "Case Based Learning", "Cells", "Cellular Indexing of Transcriptomes and Epitopes by Sequencing", "Cessation of life", "Cherokee Indian", "Cherokee Nation Oklahoma", "Cities", "Clinic", "Clinical Research", "Clinical Research Protocols", "Cotinine", "Cytomegalovirus", "Cytometry", "Data", "Degenerative polyarthritis", "Development", "Diagnosis", "Disease Outcome", "Dissemination and Implementation", "Early Diagnosis", "Early Intervention", "Early treatment", "Enrollment", "Environmental Exposure", "Environmental Impact", "Environmental Risk Factor", "Epstein-Barr virus early antigen", "Evaluation", "Exanthema", "Fatigue", "Foundations", "Future", "Genomics", "Goals", "Grant", "Health", "Health system", "Heart", "Human Herpesvirus 4", "Immune", "Immune System Diseases", "Immunophenotyping", "Individual", "Infection", "Infrastructure", "Legal patent", "Long COVID", "Lung", "Lupus", "Malaise", "Measures", "Medical Research", "Mentors", "Methods", "Morbidity - disease rate", "Myalgia", "Native American Research Center for Health", "Native Americans", "Oklahoma", "Outcome", "Pathway interactions", "Patients", "Population", "Prevention", "Primary Health Care", "Production", "Provider", "Race", "Rheumatism", "Rheumatoid Arthritis", "Rheumatology", "Rivers", "SARS-CoV-2 infection", "Scleroderma", "Self Tolerance", "Symptoms", "Systemic Lupus Erythematosus", "Systemic Scleroderma", "Testing", "Thrombosis", "Time", "Vaccines", "Viral", "Virus Diseases", "Vitamin D Deficiency", "Work", "autoimmune rheumatologic disease", "base", "care providers", "coronavirus disease", "cytokine", "immunoregulation", "improved outcome", "infection rate", "mortality", "multiple omics", "novel", "participant enrollment", "programs", "proteogenomics", "response", "rheumatologist", "single-cell RNA sequencing", "smoking exposure", "systemic autoimmune disease", "tribal community", "tribal member" ], "approved": true } }, { "type": "Grant", "id": "10543", "attributes": { "award_id": "1C06OD034121-01", "title": "National Ferret Research and Resource Institute (NFRRI) at University of Iowa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23882, "first_name": "CHARLES ASHLEY", "last_name": "Barnes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 7975000, "principal_investigator": { "id": 26554, "first_name": "JOHN F", "last_name": "ENGELHARDT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "While genetic mouse models have been the backbone of translational biomedical research for the past four decades, mice often fail to model human disease due to species-specific differences in the cell biology of the affected organs, as well as the evolutionary divergence of their genome. The ferret has proven an excellent species for modeling infectious disease (including SARS-CoV2) and human diseases of the brain, pancreas, and lung when mice have failed. The University of Iowa (UI) is the only location in the world capable of genetically engineering ferrets with multiple precise genetic alterations previously only achievable in mice. This technology has enabled the construction of genetic ferret models capable of fate mapping stem cell compartments (i.e., lineage tracing), modeling human diseases including those with humanized genetic loci, and conditional genetics using Cre recombinase. A federally-funded National Ferret Research and Resource Center was formed eight years ago, which provides services for the creation of new genetic ferret models, performing research studies in ferrets, and the distribution of tissues and cells from existing genetic lines. This national resource has provided services to more than 129 academic investigators,108 of which are outside the UI, and currently has 8 contracts with biotechnology companies seeking to develop therapies for genetic and acquired diseases using ferret models. These services have exceeded the capacity of facilities for both performing research in ferrets and housing ferrets on the UI campus. This proposal seeks to design and construct a research facility that will house the National Ferret Research and Resource Institute (NFRRI) on the UI campus. The proposed facility has been designed to maximize synergy and minimize overlap with existing facilities at UI and will be adjacent and connected to existing ferret expansion housing (referred to as the BSRF facility). The NFRRI will contain state- of-the-art equipment for genetically engineering ferret zygotes and performing research in ferrets. Procedural space will include a USDA-compliant sterile surgical suite and separate microinjection room for model creation. In addition to wet lab research space, specialized procedural suites will accommodate nebulization, pulmonary function testing, and specialized imaging equipment. The NFRRI will primarily provide services to academic investigators outside UI and for-profit biotechnology companies, but will also provide ferret models for research that will occur on the main UI campus in existing research facilities. Furthermore, the chosen location for the facility has adjacent land for future expansion of research space and ferret housing with a long-term strategic plan that recruits next-generation leaders of the NFRRI and capitalizes on existing relationships with for-profit biotechnology companies seeking to develop therapies for human diseases in preclinical ferret models. The short- and long-term strategic goals of the NFRRI will be facilitated through financial partnerships with the University of Iowa (cost sharing of the NFRRI building), Cystic Fibrosis Foundation, and Marshall Farms (the largest breeder of ferrets for research).", "keywords": [ "2019-nCoV", "Affect", "Biomedical Research", "Biotechnology", "Brain Diseases", "Cell Compartmentation", "Cells", "Cellular biology", "Contracts", "Cost Sharing", "Cystic Fibrosis", "Disease", "Drug or chemical Tissue Distribution", "Enterobacteria phage P1 Cre recombinase", "Equipment", "Farm", "Ferrets", "Foundations", "Funding", "Future", "Genetic", "Genetic Engineering", "Genome", "Goals", "Housing", "Image", "Institutes", "Iowa", "Location", "Lung diseases", "Microinjections", "Modeling", "Mus", "Mutation", "Nebulizer", "Operative Surgical Procedures", "Organ", "Pancreatic Diseases", "Pulmonary function tests", "Research", "Research Personnel", "Resources", "Services", "Sterility", "Strategic Planning", "Technology", "United States Department of Agriculture", "Universities", "Vertebral column", "design", "design and construction", "genomic locus", "human disease", "human model", "infectious disease model", "mouse model", "next generation", "pre-clinical", "recruit", "research facility", "research study", "stem cells", "synergism", "therapy development", "zygote" ], "approved": true } }, { "type": "Grant", "id": "10599", "attributes": { "award_id": "4R42MH127971-02", "title": "Developing an app-based behavioral intervention to help depressed individuals return to work", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 11535, "first_name": "Adam", "last_name": "Haim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2024-08-31", "award_amount": 664615, "principal_investigator": { "id": 24606, "first_name": "James William", "last_name": "Griffith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1760, "ror": "", "name": "INSPIRATION AT WORK, INC.", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24607, "first_name": "Alexandra", "last_name": "Levit", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24608, "first_name": "Stewart Aaron", "last_name": "Shankman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1760, "ror": "", "name": "INSPIRATION AT WORK, INC.", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Significance: The overarching goal of this proposal is to develop an intervention to help unemployed individuals with major depressive disorder (MDD) return to work. Individuals who lose their jobs are at risk for MDD and other psychiatric disorders. Because a core feature of MDD is decreased motivation, unemployed individuals with MDD can enter a `vicious cycle' where their depression leads to reduced motivation to seek work, which creates further financial hardship, which leads to worse depression and even suicide. The unprecedented impact that the COVID-19 pandemic has had on rates of depression and unemployment, has elucidated the clear need for interventions to help individuals with MDD return to work after getting laid off. Investigators: This STTR Fast Track grant brings together PeopleResults (a female-owned organizational development firm), diverse stakeholders (e.g., job seekers, community-based organizations), and Northwestern University researchers (e.g., psychologists, implementation and e-health scientists), to develop and test the efficacy of DRIVEN (Depression Return-to-work InterVEntioN). Innovation: DRIVEN is an innovative behavioral intervention that integrates evidenced-based strategies from cognitive-behavior therapy (e.g., behavioral activation techniques to improve positive affect and drive) with job-seeking and career counseling (e.g., interview coaching, how to customize job applications). DRIVEN will be a 6-week intervention largely delivered via a smartphone application (e.g., webinars, customized goals, with gamified features). However, given that e-health interventions are often plagued by high rates of attrition, DRIVEN will include multiple components designed to increase engagement, by increasing social support and accountability (e.g., biweekly live sessions with a job coach, email check-ins, gamified exercises, anonymous social media support platform). Our comprehensive commercialization plan also ensures that DRIVEN will reach job-seekers in need as it largely focuses on marketing to companies looking for outplacement services, i.e., resources provided by employers to recently laid off employees, in order to reduce the reputational fallout that companies risk following significant layoffs. Approach: Phase I will use user-centered design methodology (e.g., an advisory committee consisting of job-seekers, potential customers, experts in human resources) to design, develop, and alpha- and beta-test a prototype of DRIVEN. Phase II will test the efficacy of DRIVEN in a randomized controlled trial of 125 job seekers by comparing DRIVEN to a control condition consisting of self-guided job-seeking. Phase II will also utilize auto-regressive modelling with intensive longitudinal data to test for mediators of change (e.g., whether improvements in depression lead to greater job- seeking, and/or vice versa) Impact: DRIVEN will meet the high societal need resulting from the COVID-19 pandemic – helping the many unemployed Americans with MDD find meaningful and durable careers. While COVID-19 will (hopefully) be in the past by the end of this 3-year project, there will continue to be a need for interventions to help job-seekers with depression nimbly and successfully find work.", "keywords": [ "2019-nCoV", "Advisory Committees", "Affect", "American", "Anhedonia", "Behavior", "Behavior Therapy", "Behavioral", "Businesses", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "Cognitive", "Cognitive Therapy", "Communities", "Custom", "Data", "Depressed mood", "Development", "Dissemination and Implementation", "Electronic Mail", "Emotional disorder", "Employee", "Employment", "Ensure", "Evidence based treatment", "Exercise", "Exhibits", "Female", "Financial Hardship", "Goals", "Grant", "Health", "Hour", "Human Resources", "Individual", "Intervention", "Interview", "Job Application", "Lead", "Major Depressive Disorder", "Marketing", "Measures", "Mediator of activation protein", "Mental Depression", "Mental disorders", "Methodology", "Modeling", "Motivation", "Occupations", "Participant", "Persons", "Phase", "Private Sector", "Psychologist", "Randomized Controlled Trials", "Research Personnel", "Resources", "Risk", "Sampling", "Scientist", "Services", "Small Business Technology Transfer Research", "Social Accountability", "Social support", "Suicide", "Techniques", "Testing", "Treatment Efficacy", "Unemployment", "Universities", "Vocational Guidance", "Wages", "Work", "arm", "base", "career", "commercialization", "depressive symptoms", "design", "eHealth", "efficacy evaluation", "efficacy testing", "evidence base", "experience", "flexibility", "follow-up", "implementation efforts", "improved", "innovation", "multi-component intervention", "multidisciplinary", "novel coronavirus", "pandemic disease", "positive emotional state", "programs", "prototype", "psychologic", "response", "skills", "smartphone Application", "social media", "stressor", "suicidal risk", "therapy design", "therapy development", "treatment strategy", "user centered design", "webinar" ], "approved": true } }, { "type": "Grant", "id": "10591", "attributes": { "award_id": "1R01AI170839-01", "title": "Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22533, "first_name": "Christopher E.", "last_name": "Beisel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-09", "end_date": "2027-08-31", "award_amount": 531652, "principal_investigator": { "id": 26618, "first_name": "Jackie", "last_name": "Cliff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26619, "first_name": "Eliana", "last_name": "Lacerda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1630, "ror": "", "name": "LONDON SCH/HYGIENE & TROPICAL MEDICINE", "address": "", "city": "", "state": "", "zip": "", "country": "UNITED KINGDOM", "approved": true }, "abstract": "/ ABSTRACT Our research project, entitled “Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect”, aims to validate or refute the findings of our preliminary study on the role of human herpesviruses on the severity of symptoms in ME/CFS, and to determine if the virus reactivation is a cause or a consequence of the immune dysregulation. We will follow-up a larger number of consenting individuals (n=306), using our rigorous protocols designed to recruit participants to the UK ME/CFS Biobank (UKMEB). We have consent to re-contact UKMEB participants with ME/CFS (including those with a severe form of disease), and non-diseased controls (n=>500), with clinical assessments and collection of biosamples (blood and saliva). We will also recruit another comparison group, consisting of people with Long-COVID presenting with symptoms typical of ME/CFS (n=30), as well as people who did not develop long-term post-acute sequelae of COVID-19 after acute illness (Short COVID: n=30). The study population will comprise individuals from 18 - 60 years old, who have a diagnosis for ME/CFS or Long COVID with ME/CFS, as well as healthy controls and people who had Short COVID, in compliance with inclusion and exclusion criteria. We will perform a longitudinal analysis of people living with ME/CFS to determine the association and temporal relationship between HHV-6B DNA concentration and ME/CFS symptom severity, measuring viral DNA in saliva monthly for 6 months, alongside symptom scoring. To confirm that increases in HHV-6B DNA in saliva reflect systemic reactivation, we will measure blood viral RNA, DNA and protein, with the hypothesis that saliva RNA will correlate with saliva DNA concentration, and that all will increase together when ME/CFS symptoms are elevated. We will also measure frequency, phenotype and function of HHV-6B-reactive CD4+ and CD8+ T cells in people with ME/CFS. using flow cytometry, and will investigate the immunosuppressive effects of HHV-6B on antigen presentation in macrophages in ME/CFS using gene expression analysis. We hypothesize that HHV- 6B-specific T cells expand as ME/CFS symptoms worsen but are ineffective in for HHV-6B control, and we will test whether similar changes are observed in those with Long COVID in people who fulfill the diagnostic criteria for ME/CFS. Our goal, which stems from our successful pilot study, is to establish whether HHV-6B reactivation is causal in ME/CFS pathogenesis, and generate biological evidence which will inform targeted interventions such as vaccine development.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Affect", "Antigen Presentation", "Antigen-Presenting Cells", "Bacterial Infections", "Biological", "Biological Assay", "Blood", "Blood specimen", "CD8-Positive T-Lymphocytes", "COVID-19", "Cell physiology", "Cells", "Characteristics", "Chemical Exposure", "Chronic Fatigue Syndrome", "Clinical", "Clinical assessments", "Collection", "Consent", "Cryopreservation", "DNA", "Data", "Data Collection", "Development", "Diagnosis", "Diagnostic tests", "Disease", "Endocrine", "Enrollment", "Etiology", "Event", "Evidence based treatment", "Exclusion Criteria", "Exertion", "Family member", "Fatigue", "Flow Cytometry", "Frequencies", "Funding", "Gene Expression Profiling", "Goals", "HHV-6B", "Herpesviridae", "Human", "Immune", "Immune response", "Immunity", "Immunologic Surveillance", "Immunologics", "Immunosuppression", "Individual", "Infection", "Interferon Type II", "Interleukin-2", "Intervention", "Knowledge", "Laboratories", "Life", "Long COVID", "Measures", "Multiple Sclerosis", "Mycoses", "Nature", "Outcome", "Participant", "Pathogenesis", "Patient Recruitments", "Peripheral Blood Mononuclear Cell", "Persons", "Phenotype", "Pilot Projects", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Prognostic Marker", "Proteins", "Protocols documentation", "RNA", "Recurrence", "Relapse", "Research Project Grants", "Role", "Saliva", "Salivary", "Severities", "Severity of illness", "Stress", "Symptoms", "Syndrome", "System", "T cell response", "T-Lymphocyte", "TNF gene", "Testing", "Time", "United States National Institutes of Health", "Viral", "Viral Markers", "Viral Proteins", "Virus", "Virus Diseases", "Work", "antigen-specific T cells", "base", "biobank", "clinical phenotype", "cohort", "comparison group", "coronavirus disease", "design", "diagnostic criteria", "digital", "epidemiology study", "follow-up", "inclusion criteria", "latent infection", "longitudinal analysis", "macrophage", "monocyte", "post SARS-CoV-2 infection", "recruit", "relating to nervous system", "saliva sample", "sample collection", "stem", "stressor", "study population", "vaccine development", "vaccine immunotherapy", "viral DNA", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "10535", "attributes": { "award_id": "1R01NR020482-01A1", "title": "Leveraging community-based behavioral health to increase vaccine uptake in Latinx adults with mental illness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 6234, "first_name": "Dionne", "last_name": "Godette", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-26", "end_date": "2027-06-30", "award_amount": 593184, "principal_investigator": { "id": 26545, "first_name": "Rocio", "last_name": "Calvo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26546, "first_name": "Kirsten", "last_name": "Davison", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26547, "first_name": "SEBASTIEN", "last_name": "HANEUSE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 425, "ror": "https://ror.org/02n2fzt79", "name": "Boston College", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Latinxs, particularly those with mental illness, are at higher risk of COVID-19 infection, and associated morbidity and mortality, and yet have lower rates of vaccination, than non-Latinx whites. This pattern is not unique to COVID-19; it has been observed for other infectious diseases, including seasonal influenza. Vaccine hesitancy, understood as a delay in the acceptance of vaccination despite availability of vaccination services, is the primary roadblock for COVID-19 and influenza vaccination among Latinxs. Theoretical frameworks endorsed by the SAGE working group on vaccine hesitancy, and prior research, illustrate that interventions to reduce vaccine hesitancy and increase vaccine uptake in Latinxs should adopt strategies that: increase vaccine confidence and convenience; reduce vaccine complacency; and respond to contextual, individual and vaccine-related factors driving hesitancy, which include but are not limited to the social determinants of health and structural racism. While a variety of strategies have been developed to address vaccine hesitancy in priority populations, the potential role of behavioral health in community-based integrated health care settings has been overlooked. Yet behavioral health, particularly within federally qualified health centers (FQHCs) which target social determinants of health, may be an ideal setting to reach Latinxs, and other priority populations with mental illness, to address vaccine hesitancy and promote vaccine uptake. In collaboration with East Boston Neighborhood Health Center (EBNHC), the largest FQHC of Massachusetts, the proposed study will evaluate a novel Motivational Interviewing (MI) behavioral intervention to reduce vaccine hesitancy and increase COVID-19 and influenza vaccine uptake in Latinx adults with mental illness. Key to the intervention is that the proposed MI protocol explicitly acknowledges cultural values that are central to the Latinx population and that impact their interactions with health care providers. Additionally, the intervention has been specifically designed to be feasible and readily implemented in community-based settings, and to be sustainable in the long-term regardless of how the rapidly changing COVID-19 vaccination landscape evolves. To rigorously evaluate the intervention, we will conduct a pragmatic multiple-period cluster-randomized crossover trial within four BH programs at EBNHC; key to this design is that each program serves as its own control and that the multiple switches enhance statistical power. To our knowledge, this will be the first study to rigorously examine the potential role of BH providers in increasing vaccine uptake among Latinx adults with mental illness, a particularly vulnerable population. Key to the anticipated impact is the partnership between the academia-based research team and colleagues at EBNHC which, in turn, will support the rapid translation of evidence into practice together with a model for sustainable collaboration and national scaleup.", "keywords": [ "Academia", "Address", "Adopted", "Adult", "Automobile Driving", "Behavior Therapy", "Boston", "COVID-19", "COVID-19 morbidity", "COVID-19 pandemic", "COVID-19 risk", "COVID-19 vaccination", "COVID-19 vaccine", "Caring", "Collaborations", "Communicable Diseases", "Communities", "Counseling", "Country", "Coupled", "Cross-Over Trials", "Death Rate", "Development", "Diagnosis", "Discrimination", "Elements", "Federally Qualified Health Center", "Health Personnel", "Health Services", "Hispanic", "Individual", "Influenza vaccination", "Intervention", "Knowledge", "Language", "Latinx", "Latinx population", "Leadership", "Massachusetts", "Mental Health", "Mental disorders", "Modeling", "Morbidity - disease rate", "Neighborhood Health Center", "Neighborhoods", "Pathway interactions", "Patients", "Pattern", "Plant Roots", "Population", "Positioning Attribute", "Protocols documentation", "Provider", "Randomized", "Research", "Research Personnel", "Risk", "Role", "SARS-CoV-2 infection", "Safety", "Series", "Services", "Structural Racism", "Time", "Training", "Translations", "Trauma", "Trust", "Universities", "Vaccinated", "Vaccination", "Vaccines", "Vulnerable Populations", "World Health Organization", "base", "behavioral health", "behavioral health intervention", "clinical practice", "college", "coronavirus disease", "cultural values", "design", "effectiveness evaluation", "effectiveness testing", "evidence base", "experience", "global health", "health care settings", "health disparity", "high risk", "hospitalization rates", "influenza virus vaccine", "innovation", "intervention effect", "mortality", "motivational enhancement therapy", "novel", "pandemic disease", "person centered", "point of care", "programs", "response", "scale up", "seasonal influenza", "social health determinants", "theories", "treatment as usual", "trial design", "uptake", "vaccine acceptance", "vaccine access", "vaccine distribution", "vaccine hesitancy", "vaccine refusal", "working group" ], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1424, "count": 14236 } } }